<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id>
      <journal-title-group>
        <journal-title>BMC Cancer</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2407</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26555668</article-id>
      <article-id pub-id-type="pmc">4640161</article-id>
      <article-id pub-id-type="publisher-id">1908</article-id>
      <article-id pub-id-type="doi">10.1186/s12885-015-1908-3</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>From palliative to curative treatment - stage IV mucinous adenocarcinoma, successfully treated with metronomic capecitabine in combination with Bevacizumab and surgery- a case report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Vernmark</surname>
            <given-names>Karolina</given-names>
          </name>
          <address>
            <phone>+46-10-1032634</phone>
            <email>karolina.vernmark@regionostergotland.se</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Albertsson</surname>
            <given-names>Maria</given-names>
          </name>
          <address>
            <email>maria.albertsson@regionostergotland.se</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bj&#xF6;rnsson</surname>
            <given-names>Bergthor</given-names>
          </name>
          <address>
            <email>bergthor.bjornsson@regionostergotland.se</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gasslander</surname>
            <given-names>Thomas</given-names>
          </name>
          <address>
            <email>thomas.gasslander@regionostergotland.se</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sandstr&#xF6;m</surname>
            <given-names>Per</given-names>
          </name>
          <address>
            <email>per.sandstrom@regionostergotland.se</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sun</surname>
            <given-names>Xiao-Feng</given-names>
          </name>
          <address>
            <email>xiao-feng.sun@liu.se</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Holmqvist</surname>
            <given-names>Annika</given-names>
          </name>
          <address>
            <email>annika.holmqvist@regionostergotland.se</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Department of Clinical and Experimental Medicine, Link&#xF6;ping University, Link&#xF6;ping, Sweden </aff>
        <aff id="Aff2"><label>2</label>Department of Oncology, Link&#xF6;ping University, S-58185 Link&#xF6;ping, Sweden </aff>
        <aff id="Aff3"><label>3</label>Departement of Surgery, Link&#xF6;ping University, Link&#xF6;ping, Sweden </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>10</day>
        <month>11</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>10</day>
        <month>11</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2015</year>
      </pub-date>
      <volume>15</volume>
      <elocation-id>884</elocation-id>
      <history>
        <date date-type="received">
          <day>18</day>
          <month>3</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>4</day>
          <month>11</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Vernmark et al. 2015</copyright-statement>
        <license license-type="OpenAccess">
          <license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Mucinous adenocarcinoma (MAC) represents 6-19 % of all colorectal carcinoma. It is associated with poorer response to chemotherapy and chemoradiotherapy.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>A 27-year-old Swedish woman presented with stomach pain and weight loss, and was diagnosed with locally advanced MAC in the transverse colon as well as 3 liver metastases. Neoadjuvant treatment with fluorouracil, folinic acid and oxaliplatin (FLOX) failed due to several infections, pulmonary embolism and deteriorated performance status. The patient was therefore considered palliative. Palliative treatment with metronomic capecitabine 500&#xA0;mg&#x2009;&#xD7;&#x2009;2 daily and bevacizumab every other week were initiated. After 4&#xA0;months of treatment the tumors had regressed and the patient was able to undergo radical surgery, thereby changing the treatment intention from palliative to curative. No adjuvant chemotherapy was given. There were no signs of recurrence 9&#xA0;months later.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>The role of the combination of metronomic capecitabine and bevacizumab in patients with MAC merits further investigation.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Mucinous adenocarcinoma</kwd>
        <kwd>Bevacizumab</kwd>
        <kwd>Metronomic capecitabine</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>Mucinous adenocarcinoma (MAC) represents about 6&#x2013;19 % of colorectal carcinomas (CRC) [<xref ref-type="bibr" rid="CR1">1</xref>]. The WHO defines MAC as an adenocarcinoma in which at least 50% of the cancer tissue is composed of mucin [<xref ref-type="bibr" rid="CR2">2</xref>].</p>
      <p>Numerous studies have shown conflicting results regarding the prognosis of MAC compared to the more common non-mucinous adenocarcinoma (NMAC) [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. It has however been shown that MAC is less likely to be resected with negative surgical margins [<xref ref-type="bibr" rid="CR4">4</xref>], more often metastasizes to lymph nodes [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>] and generally presents at a later stage compared to NMAC [<xref ref-type="bibr" rid="CR2">2</xref>]. MAC is also more prone to local recurrence [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR7">7</xref>] as well as peritoneal carcinomatosis [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Although the characteristics of MAC have not been fully clarified, due to the low incidence of this type of tumor, studies have shown that MAC shows less p53 and p21 expression and less APC mutations compared to NMAC [<xref ref-type="bibr" rid="CR2">2</xref>]. There also appears to be an increased frequency in BRAF mutation [<xref ref-type="bibr" rid="CR1">1</xref>] and increased microsatellite instability (MSI) [<xref ref-type="bibr" rid="CR9">9</xref>]. In our clinic it is not praxis to analyze these markers because the results would not affect our choice of treatment.</p>
      <p>Compared to NMAC, MAC is associated with a poorer response to chemotherapy and chemoradiotherapy [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>], resulting in some restrictiveness to treatment. Here, we present a case of successful preoperative treatment and surgery of a patient with stage IV MAC.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p>A 27-year-old Swedish woman with no family history of cancer presented with stomach pain, rectal bleeding and weight loss. A computed tomography (CT) revealed an 80 &#xD7; 55&#xA0;mm tumor in the transversal colon. Colonoscopy showed a stricturating, voluminous tumor with irregular polyps. Most of the tumor surface was covered with white necrotic tissue. Multiple biopsies from the site showed suspected adenocarcinoma, but the result was not conclusive. A biopsy was then taken from the abdominal wall, and MAC with K-ras mutation in codon 12, gene pGly 12ASP (c.35G&#x2009;&gt;&#x2009;A) was found.</p>
      <p>Two months after the prior CT, a new CT showed that the tumor had grown rapidly, measuring 150&#x2009;&#xD7;&#x2009;90&#xA0;mm (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1a</xref>). It was locally advanced, seemed to infiltrate the duodenum and the mesentery, and involved the abdominal wall. Moreover, 3 small liver metastases were discovered, sized 12&#xA0;mm, 7&#xA0;mm and 4&#xA0;mm, respectively. Carcinoembryotic antigen (CEA) was &lt;5&#xA0;&#x3BC;g/L and cancer antigen 19&#x2013;9 (CA 19&#x2013;9) was 27 kE/L, both within the normal range.<fig id="Fig1"><label>Fig. 1</label><caption><p>A computed tomography (CT) with contrast before treatment (<bold>a</bold>), 2&#xA0;months after FLOX treatment (<bold>b</bold>), 4&#xA0;months after treatment with metronomic capecitabine/bevacizumab (<bold>c</bold>) and 9&#xA0;months after surgery (<bold>d</bold>)</p></caption><graphic xlink:href="12885_2015_1908_Fig1_HTML" id="d30e414"/></fig></p>
      <p>The primary tumor was originally considered non-resectable at multidisciplinary conference (MDC) and chemotherapy with neoadjuvant intention was initiated. The patient received 3&#xA0;cycles of fluorouracil and oxaliplatin (FLOX), but unfortunately suffered from several infections and the dose was gradually reduced (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). Even so, she rapidly deteriorated. She lost weight, slept most of the day and was dependent on parenteral nutrition (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). She had anemia, thrombocytosis and hypoalbuminemia (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>), and also suffered from a pulmonary embolism. A CT scan showed similar tumor size compared to the previous CT (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1b</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Patient&#x2019;s BMI, chemotherapy doses given and performance status</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Year</th><th>Month</th><th>BMI</th><th>Treatment</th><th>Dose</th><th>Performance status</th></tr></thead><tbody><tr><td>2011</td><td/><td>31.2</td><td/><td/><td/></tr><tr><td>2013</td><td>Feb</td><td>29.4</td><td>FLOX C1</td><td>Oxaliplatin: 150&#xA0;mg Fluorouracil: 950&#xA0;mg Calciumfolinat: 110&#xA0;mg</td><td>0</td></tr><tr><td/><td>March</td><td>28.7</td><td>FLOX C2</td><td>Oxaliplatin: 140&#xA0;mg Fluorouracil: 900&#xA0;mg Calciumfolinat: 100&#xA0;mg</td><td>1</td></tr><tr><td/><td>April</td><td>27.8</td><td>FLOX C3</td><td>Oxaliplatin: 120&#xA0;mg Fluorouracil: 720&#xA0;mg Calciumfolinat: 100&#xA0;mg</td><td>1</td></tr><tr><td/><td>June</td><td>29.2</td><td>Capecitabine</td><td>500mgx1</td><td>1-2</td></tr><tr><td/><td>July</td><td/><td>Capecitabine/ Bevacizumab C1</td><td>500&#xA0;mg&#x2009;&#xD7;&#x2009;2/ 350&#xA0;mg</td><td>1-2</td></tr><tr><td/><td>Aug</td><td/><td>Capecitabine/ Bevacizumab C2</td><td>500&#xA0;mg&#x2009;&#xD7;&#x2009;2/ 350&#xA0;mg</td><td>0-1</td></tr><tr><td/><td/><td/><td>Capecitabine/ Bevacizumab C3</td><td>500&#xA0;mg&#x2009;&#xD7;&#x2009;2/ 350&#xA0;mg</td><td/></tr><tr><td/><td>Sept</td><td/><td>Capecitabine/ Bevacizumab C4</td><td>500&#xA0;mg&#x2009;&#xD7;&#x2009;2/ 350&#xA0;mg</td><td/></tr><tr><td/><td/><td/><td>Capecitabine/ Bevacizumab C5</td><td>500&#xA0;mg&#x2009;&#xD7;&#x2009;2/ 350&#xA0;mg</td><td/></tr><tr><td/><td>Oct</td><td>29.8</td><td>Capecitabine/ Bevacizumab C6</td><td>500&#xA0;mg&#x2009;&#xD7;&#x2009;2/ 350&#xA0;mg</td><td>0-1</td></tr><tr><td/><td/><td/><td>Capecitabine/ Bevacizumab C7</td><td>500&#xA0;mg&#x2009;&#xD7;&#x2009;2/ 350&#xA0;mg</td><td/></tr><tr><td>2014</td><td>Jan</td><td>31.2</td><td/><td/><td>0</td></tr></tbody></table></table-wrap><fig id="Fig2"><label>Fig. 2</label><caption><p>Platelet concentration (TPC), hemoglobin (Hb) and albumin levels over time during treatment</p></caption><graphic xlink:href="12885_2015_1908_Fig2_HTML" id="d30e662"/></fig></p>
      <p>The therapy was now focused on palliation and she was referred to palliative care. The treatment was switched to low dose metronomic (LDM) capecitabine 500&#xA0;mg&#x2009;&#xD7;&#x2009;2 (500&#xA0;mg twice daily without interruption) and bevacizumab 350&#xA0;mg every other week. Within a short time she began to feel better, being able to stay up most of the day. After 2&#xA0;months she described herself as feeling fresh and alert, and had gotten her appetite back. Her blood tests were restored to normal. After 3&#xA0;months she was no longer in need of parenteral nutrition. She did not report any side effects of the given treatment. After 4&#xA0;months a CT showed some regression in tumor size but clearly less solid component and low attenuating areas, indicating necrosis (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1c</xref>). At a new MDC the tumor was deemed resectable. Four and a half months after she began treatment with capecitabine/bevacizumab, she had surgery with right hemicolectomy, mesentery resection and omentectomy. Parts of the right rectus abdominis muscle were removed along with the tumor overgrowth. In the same operation, 3 of the liver metastases in segments 1, 3 and 4b were also removed. Yet another liver metastasis in segment 8 was identified with intraoperative contrast-enhanced ultrasound. It measured 5&#x2013;6&#xA0;mm and was treated with intraoperative radiofrequency treatment. Histopathological examination confirmed the diagnosis of a moderately differentiated MAC in the colon, measuring 90 &#xD7; 60&#xA0;mm. (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>) In addition, there was an 80x80 mm portion of the tumor that engaged the abdominal wall. There were large areas of necrosis in the tumor. Perineural growth was seen but no lymphovascular invasion. None of the 34 surgically removed lymph nodes contained metastasis. In the liver, 3 metastases of MAC were found, measuring 15 &#xD7; 18&#xA0;mm, 6 &#xD7; 15 &#xD7; 8&#xA0;mm and 18 &#xD7; 15 &#xD7; 11&#xA0;mm, respectively. There was also an incidental finding of a neuroendocrine tumor grade 1, pT1a, in the appendix.<fig id="Fig3"><label>Fig. 3</label><caption><p>Histologic hematoxylin and eosin stained paraffin section of the patient&#x2019;s tumor in the colon (<bold>a</bold>) and in the liver (<bold>b</bold>), respectively</p></caption><graphic xlink:href="12885_2015_1908_Fig3_HTML" id="d30e685"/></fig></p>
      <p>The patient suffered from a postoperative infection, but recovered well. No adjuvant chemotherapy was given. She is under follow up and there are no signs of recurrence 9&#xA0;months (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1d</xref>) after surgery.</p>
    </sec>
    <sec id="Sec3" sec-type="discussion">
      <title>Discussion</title>
      <p>There have been several studies with conflicting results regarding the prognosis of patients with MAC compared to NMAC [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. A meta-analysis from 2011, with 44 studies and 222 256 patients with CRC included, stated that mucinous differentiation resulted in an increased hazard of death [<xref ref-type="bibr" rid="CR2">2</xref>]. It has been suggested that a worse prognosis could be due to the fact that MAC more often present at a more advanced stage [<xref ref-type="bibr" rid="CR12">12</xref>], but the meta-analysis from 2011 showed that a worse prognosis persisted after correction for stage [<xref ref-type="bibr" rid="CR2">2</xref>].</p>
      <p>On the other hand, in 2012 a study of 244 794 patients with CRC showed that there was no difference between the groups when MAC was located in the colon. The exception was signet-ring cell adenocarcinoma, which had a significantly worse prognosis, regardless of stage and location.</p>
      <p>A disadvantage when comparing studies including patients with MAC is that even though WHO has defined MAC, several studies have used their own definition, often with a higher percentage of mucinous component, and no distinction between MAC and signet-ring cell carcinoma [<xref ref-type="bibr" rid="CR2">2</xref>]. Due to the lack of a precise definition of MAC, it is difficult to interpret the data.</p>
      <p>However, studies have shown that MAC is less likely to respond to radiotherapy and conventional chemotherapy [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. This may be due to the interference with immunologic recognition of tumor cells by masking antigenic epitopes and inhibiting lymphocytic infiltration [<xref ref-type="bibr" rid="CR13">13</xref>].</p>
      <p>LDM chemotherapy seems likely to work through completely different mechanisms than conventional chemotherapy. The mechanisms of LDM chemotherapy are believed to be primarily related to inhibition of tumor angiogenesis [<xref ref-type="bibr" rid="CR14">14</xref>], which is also the target for vascular endothelial growth factor inhibitors such as bevacizumab. The anti-angiogenic effect of LDM chemotherapy is believed to be due to either direct killing or inhibiting of endothelial cells in the tumor vasculature, or killing of bone-marrow-derived endothelial progenitor cells. Continuous administration of LDM chemotherapy prevents endothelial cells from recovering, which leads to sustained anti-angiogenic effect. In addition, studies have shown that LDM chemotherapy stimulates the immune system through inhibition of T<sub>reg</sub> cells, which leads to increased activation of both tumor specific and tumor un-specific effector cells. LDM also activates dendritic cells, thereby further inducing the immune-stimulatory effect.</p>
      <p>It has been shown that LDM chemotherapy, besides directly affecting tumor cells, also enhances the effect of targeting drugs. Most clinical trials have shown that LDM chemotherapy is well tolerated; high grade toxicity is rare or not found [<xref ref-type="bibr" rid="CR14">14</xref>]. Many phase II studies have shown the clinical benefit of LDM chemotherapy, including promising tumor control rates and an excellent safety profile [<xref ref-type="bibr" rid="CR15">15</xref>].</p>
      <p>The concept of LDM capecitabine has been successfully used predominately in breast cancer [<xref ref-type="bibr" rid="CR16">16</xref>] but also in metastatic CRC [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Miger et al. [<xref ref-type="bibr" rid="CR17">17</xref>] retrospectively studied 35 patients with stage IV gastrointestinal cancer that had been treated with LDM capecitabine. Twenty-two of the patients had CRC. The treatment was well-tolerated and 40 % of the patients with CRC had stable disease after 2&#xA0;months. Two of the patients with CRC lived more than 24&#xA0;months after initiating treatment. These two patients both had MAC. Romiti et al. [<xref ref-type="bibr" rid="CR18">18</xref>] retrospectively studied 68 patients with recurrent CRC that had been treated with LDM capecitabine. They concluded that the treatment was well-tolerated and that 19 % of the patients were progression free for more than 6&#xA0;months. The median overall survival was 23&#xA0;months for responders.</p>
      <p>According to a recently published review, there have been several studies analyzing the effect of the combination of LDM chemotherapy and bevacizumab in patients with glioblastoma multiforme, metastatic ovarian cancer, advanced breast cancer and non-small cell lung cancer [<xref ref-type="bibr" rid="CR19">19</xref>]. These studies have demonstrated clinical evidence of anti-tumor efficacy, although interpretation of the studies is generally limited by small sample sizes and lack of a control arm. To our knowledge there is only one study which has investigated the effect of LDM chemotherapy and bevacizumab in patients with metastatic colorectal cancer. This study, by Kelley et al., included 35 patients that had received at least two previous lines of therapy, before introducing the combination of cyclophosphamide 50&#xA0;mg daily with imatinib 400&#xA0;mg daily and bevacizumab 5&#xA0;mg/kg every 2&#xA0;weeks. The treatment was well tolerated and led to prolonged (more than 6&#xA0;months) stabilization of the disease in 20 % of patients [<xref ref-type="bibr" rid="CR20">20</xref>].</p>
      <p>The current patient had a series of unfavorable prognostic factors besides having a mucinous adenocarcinoma: rapidly growing locally advanced tumor, thrombocytosis [<xref ref-type="bibr" rid="CR21">21</xref>] and KRAS mutation [<xref ref-type="bibr" rid="CR22">22</xref>]. Conventional therapy caused severe infections and a pulmonary embolism and the dose was reduced (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>, Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). The result was disappointing, since the tumor size was unaffected. Even though the treatment was now focused on palliation, the patient was young and highly motivated to receiving treatment. The only thing deemed feasible was LDM capecitabine, which has been used in previous studies in our clinic with promising results [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. The patient was followed up frequently and when the treatment was well tolerated, it was combined with bevacizumab. After 4&#xA0;months, a reduction in tumor size was seen and the tumor center was low attenuating according to the CT. Postoperatively the center of the tumor was confirmed to be necrotic. Nine months after surgery she was still recurrence free. To our knowledge this is the only case where the cancer in a patient with multifocal metastatic MAC with colorectal origin has been successfully and completely eradicated.</p>
    </sec>
    <sec id="Sec4" sec-type="conclusion">
      <title>Conclusion</title>
      <p>LDM capecitabine in combination with bevacizumab could be an attractive therapy option for treating patients who are not eligible for more advanced treatment. As the present case exemplifies, in addition to being feasible, it could give a remarkable result. However, the described case report highlights the need for future studies to evaluate the outcome of this treatment.</p>
    </sec>
    <sec id="Sec5">
      <title>Consent</title>
      <p>Written informed consent has been obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>CA 19&#x2013;9</term>
          <def>
            <p>cancer antigen 19&#x2013;9</p>
          </def>
        </def-item>
        <def-item>
          <term>CEA</term>
          <def>
            <p>carcinoembryonic antigen</p>
          </def>
        </def-item>
        <def-item>
          <term>CRC</term>
          <def>
            <p>colorectal cancer</p>
          </def>
        </def-item>
        <def-item>
          <term>CT</term>
          <def>
            <p>computed tomography</p>
          </def>
        </def-item>
        <def-item>
          <term>FLOX</term>
          <def>
            <p>fluorouracil, folinic acid and oxaliplatin</p>
          </def>
        </def-item>
        <def-item>
          <term>LDM</term>
          <def>
            <p>low dose metronomic</p>
          </def>
        </def-item>
        <def-item>
          <term>MAC</term>
          <def>
            <p>mucinous adenocarcinoma</p>
          </def>
        </def-item>
        <def-item>
          <term>MDC</term>
          <def>
            <p>multidisciplinary conference</p>
          </def>
        </def-item>
        <def-item>
          <term>NMAC</term>
          <def>
            <p>non-mucinous adenocarcinoma</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interest.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>KV carried out the study, interpreted the results and prepared the article for publication. AH, XFS and MA participated in the study design and interpretation of the study results. AH, XFS, MA, TG, BB and PS participated in preparation of the article for publication. All authors have read and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgement</title>
      <p>We thank Dr Russell Pepin, American colleague, for language corrections. This study was funded by grants from the foundation of Oncological Clinical Research in Link&#xF6;ping.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Evertsson</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>X</given-names>
            </name>
          </person-group>
          <article-title>Clinicopathological and genetic characteristics of mucinous carcinomas in the colorectum</article-title>
          <source>Int J Oncol</source>
          <year>1999</year>
          <volume>14</volume>
          <issue>6</issue>
          <fpage>1057</fpage>
          <lpage>61</lpage>
          <pub-id pub-id-type="pmid">10339657</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Verhulst</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ferdinande</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Demetter</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ceelen</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Mucinous subtype as prognostic factor in colorectal cancer: a systematic review and meta-analysis</article-title>
          <source>J Clin Pathol</source>
          <year>2012</year>
          <volume>65</volume>
          <issue>5</issue>
          <fpage>381</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1136/jclinpath-2011-200340</pub-id>
          <pub-id pub-id-type="pmid">22259177</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hyngstrom</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>CY</given-names>
            </name>
            <name>
              <surname>Xing</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>You</surname>
              <given-names>YN</given-names>
            </name>
            <name>
              <surname>Feig</surname>
              <given-names>BW</given-names>
            </name>
            <name>
              <surname>Skibber</surname>
              <given-names>JM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base</article-title>
          <source>Ann Surg Oncol</source>
          <year>2012</year>
          <volume>19</volume>
          <issue>9</issue>
          <fpage>2814</fpage>
          <lpage>21</lpage>
          <pub-id pub-id-type="doi">10.1245/s10434-012-2321-7</pub-id>
          <pub-id pub-id-type="pmid">22476818</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Umpleby</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Ranson</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Williamson</surname>
              <given-names>RC</given-names>
            </name>
          </person-group>
          <article-title>Peculiarities of mucinous colorectal carcinoma</article-title>
          <source>Br J Surg</source>
          <year>1985</year>
          <volume>72</volume>
          <issue>9</issue>
          <fpage>715</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1002/bjs.1800720915</pub-id>
          <pub-id pub-id-type="pmid">2994793</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nozoe</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Anai</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nasu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sugimachi</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Clinicopathological characteristics of mucinous carcinoma of the colon and rectum</article-title>
          <source>J Surg Oncol</source>
          <year>2000</year>
          <volume>75</volume>
          <issue>2</issue>
          <fpage>103</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1002/1096-9098(200010)75:2&lt;103::AID-JSO6&gt;3.0.CO;2-C</pub-id>
          <pub-id pub-id-type="pmid">11064389</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Akino</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Mitomi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ohtani</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ichinoe</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Okayasu</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>High apoptotic activity and low epithelial cell proliferation with underexpression of p21(WAF1/CIP1) and p27Kip1 of mucinous carcinomas of the colorectum: comparison with well-differentiated type</article-title>
          <source>Am J Clin Pathol</source>
          <year>2002</year>
          <volume>117</volume>
          <issue>6</issue>
          <fpage>908</fpage>
          <lpage>15</lpage>
          <pub-id pub-id-type="doi">10.1309/D4QM-379U-E8J2-9R1M</pub-id>
          <pub-id pub-id-type="pmid">12047142</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Connelly</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Robey-Cafferty</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Cleary</surname>
              <given-names>KR</given-names>
            </name>
          </person-group>
          <article-title>Mucinous carcinomas of the colon and rectum. An analysis of 62 stage B and C lesions</article-title>
          <source>Arch Pathol Lab Med</source>
          <year>1991</year>
          <volume>115</volume>
          <issue>10</issue>
          <fpage>1022</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">1654871</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Halvorsen</surname>
              <given-names>TB</given-names>
            </name>
            <name>
              <surname>Seim</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Influence of mucinous components on survival in colorectal adenocarcinomas: a multivariate analysis</article-title>
          <source>J Clin Pathol</source>
          <year>1988</year>
          <volume>41</volume>
          <issue>10</issue>
          <fpage>1068</fpage>
          <lpage>72</lpage>
          <pub-id pub-id-type="doi">10.1136/jcp.41.10.1068</pub-id>
          <pub-id pub-id-type="pmid">2848059</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Messerini</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Vitelli</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>De Vitis</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Mori</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Calzolari</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Palmirotta</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Microsatellite instability in sporadic mucinous colorectal carcinomas: relationship to clinico-pathological variables</article-title>
          <source>J Pathol</source>
          <year>1997</year>
          <volume>182</volume>
          <issue>4</issue>
          <fpage>380</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="doi">10.1002/(SICI)1096-9896(199708)182:4&lt;380::AID-PATH871&gt;3.0.CO;2-U</pub-id>
          <pub-id pub-id-type="pmid">9306957</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lupinacci</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Mello</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Coelho</surname>
              <given-names>FF</given-names>
            </name>
            <name>
              <surname>Kruger</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Perini</surname>
              <given-names>MV</given-names>
            </name>
            <name>
              <surname>Pinheiro</surname>
              <given-names>RS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prognostic implication of mucinous histology in resected colorectal cancer liver metastases</article-title>
          <source>Surgery</source>
          <year>2014</year>
          <volume>155</volume>
          <issue>6</issue>
          <fpage>1062</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1016/j.surg.2014.01.011</pub-id>
          <pub-id pub-id-type="pmid">24856126</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shin</surname>
              <given-names>US</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>TW</given-names>
            </name>
            <name>
              <surname>Lim</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Yoon</surname>
              <given-names>SN</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mucinous rectal cancer: effectiveness of preoperative chemoradiotherapy and prognosis</article-title>
          <source>Ann Surg Oncol</source>
          <year>2011</year>
          <volume>18</volume>
          <issue>8</issue>
          <fpage>2232</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1245/s10434-011-1612-8</pub-id>
          <pub-id pub-id-type="pmid">21347780</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Younes</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Katikaneni</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Lechago</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>The value of the preoperative mucosal biopsy in the diagnosis of colorectal mucinous adenocarcinoma</article-title>
          <source>Cancer</source>
          <year>1993</year>
          <volume>72</volume>
          <issue>12</issue>
          <fpage>3588</fpage>
          <lpage>92</lpage>
          <pub-id pub-id-type="doi">10.1002/1097-0142(19931215)72:12&lt;3588::AID-CNCR2820721207&gt;3.0.CO;2-I</pub-id>
          <pub-id pub-id-type="pmid">8252472</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Niv</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Mucin and colorectal cancer metastasis</article-title>
          <source>Am J Gastroenterol</source>
          <year>1994</year>
          <volume>89</volume>
          <issue>5</issue>
          <fpage>665</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">8172135</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maiti</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Metronomic chemotherapy</article-title>
          <source>J Pharmacol Pharmacother</source>
          <year>2014</year>
          <volume>5</volume>
          <issue>3</issue>
          <fpage>186</fpage>
          <lpage>92</lpage>
          <pub-id pub-id-type="doi">10.4103/0976-500X.136098</pub-id>
          <pub-id pub-id-type="pmid">25210398</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lien</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Georgsdottir</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sivanathan</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Emmenegger</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <article-title>Low-dose metronomic chemotherapy: a systematic literature analysis</article-title>
          <source>Eur J Cancer</source>
          <year>2013</year>
          <volume>49</volume>
          <issue>16</issue>
          <fpage>3387</fpage>
          <lpage>95</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejca.2013.06.038</pub-id>
          <pub-id pub-id-type="pmid">23880474</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fedele</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Marino</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Orlando</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Schiavone</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Nacci</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sponziello</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer</article-title>
          <source>Eur J Cancer</source>
          <year>2012</year>
          <volume>48</volume>
          <issue>1</issue>
          <fpage>24</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejca.2011.06.040</pub-id>
          <pub-id pub-id-type="pmid">21775129</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Miger</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Holmqvist</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>XF</given-names>
            </name>
            <name>
              <surname>Albertsson</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer</article-title>
          <source>Med Oncol</source>
          <year>2014</year>
          <volume>31</volume>
          <issue>3</issue>
          <fpage>870</fpage>
          <pub-id pub-id-type="doi">10.1007/s12032-014-0870-2</pub-id>
          <pub-id pub-id-type="pmid">24510794</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Romiti</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Onesti</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Roberto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Barucca</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Tomao</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>D'Antonio</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Continuous, low-dose capecitabine for patients with recurrent colorectal cancer</article-title>
          <source>Med Oncol</source>
          <year>2015</year>
          <volume>32</volume>
          <issue>3</issue>
          <fpage>54</fpage>
          <pub-id pub-id-type="doi">10.1007/s12032-015-0496-z</pub-id>
          <pub-id pub-id-type="pmid">25638466</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Digklia</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Voutsadakis</surname>
              <given-names>IA</given-names>
            </name>
          </person-group>
          <article-title>Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status</article-title>
          <source>World J Exp Med</source>
          <year>2014</year>
          <volume>4</volume>
          <issue>4</issue>
          <fpage>58</fpage>
          <lpage>67</lpage>
          <pub-id pub-id-type="doi">10.5493/wjem.v4.i4.58</pub-id>
          <pub-id pub-id-type="pmid">25414818</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kelley</surname>
              <given-names>RK</given-names>
            </name>
            <name>
              <surname>Hwang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Magbanua</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Watt</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Beumer</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Christner</surname>
              <given-names>SM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer</article-title>
          <source>Br J Cancer</source>
          <year>2013</year>
          <volume>109</volume>
          <issue>7</issue>
          <fpage>1725</fpage>
          <lpage>34</lpage>
          <pub-id pub-id-type="doi">10.1038/bjc.2013.553</pub-id>
          <pub-id pub-id-type="pmid">24022191</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baranyai</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>J&#xF3;sa</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Krzystanek</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Eklund</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Sz&#xE1;sz</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Sz&#xE1;ll&#xE1;si</surname>
              <given-names>Z</given-names>
            </name>
          </person-group>
          <article-title>Evaluation of thrombocytosis as predictive factor in colorectal cancer</article-title>
          <source>Magy Seb</source>
          <year>2013</year>
          <volume>66</volume>
          <issue>6</issue>
          <fpage>331</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1556/MaSeb.66.2013.6.5</pub-id>
          <pub-id pub-id-type="pmid">24333978</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Phipps</surname>
              <given-names>AI</given-names>
            </name>
            <name>
              <surname>Buchanan</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Makar</surname>
              <given-names>KW</given-names>
            </name>
            <name>
              <surname>Win</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Baron</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Lindor</surname>
              <given-names>NM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers</article-title>
          <source>Br J Cancer</source>
          <year>2013</year>
          <volume>108</volume>
          <issue>8</issue>
          <fpage>1757</fpage>
          <lpage>64</lpage>
          <pub-id pub-id-type="doi">10.1038/bjc.2013.118</pub-id>
          <pub-id pub-id-type="pmid">23511557</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carstens</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Albertsson</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Successful treatment with low-dose capecitabine for disseminated esophageal adenocarcinoma</article-title>
          <source>Acta Oncol</source>
          <year>2007</year>
          <volume>46</volume>
          <issue>6</issue>
          <fpage>866</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1080/02841860701203560</pub-id>
          <pub-id pub-id-type="pmid">17653915</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
